Multifocal Neuroblastoma in Rubinstein-Taybi Syndrome Harboring a Novel CREBBP Variant Identified by Paired Whole

Yuki Fushimi1, Yasuhiro Kawai1, Dai Keino2

  • 1Division of Medical Genetics, Kanagawa Children's Medical Center, Yokohama, Japan.

Congenital Anomalies
|June 25, 2026
PubMed

Insights

Rubinstein-Taybi syndrome (RTS) patients have increased tumor risk due to CREBBP/EP300 gene variants. This case highlights a young boy with RTS and neuroblastoma, linked to a new CREBBP gene variant, suggesting a tumor predisposition factor.

Area of Science:

  • Genetics
  • Oncology
  • Developmental Biology

Background:

  • Rubinstein-Taybi syndrome (RTS) is a genetic disorder caused by germline loss-of-function variants in CREBBP or EP300.
  • These genes encode histone acetyltransferases and function as tumor suppressors, with RTS patients exhibiting increased susceptibility to various tumors.
  • While neuroblastoma has been reported in five RTS patients, germline pathogenic variants were confirmed in only two.

Purpose of the Study:

  • To report a case of neuroblastoma in a patient with Rubinstein-Taybi syndrome.
  • To investigate the genetic underpinnings of tumor predisposition in this patient.
  • To analyze the genomic profile of the neuroblastoma and germline DNA.

Main Methods:

  • Whole genome sequencing of both tumor and germline DNA.
  • Identification and characterization of germline and somatic variants.
  • Histological evaluation and risk stratification of the neuroblastoma.

Main Results:

  • A 2-year-old male with RTS and neuroblastoma was identified.
  • A de novo missense variant (c.4862T>A p.(Leu1621Gln)) in the CREBBP histone acetyltransferase (HAT) domain was found in the germline.
  • The neuroblastoma, diagnosed at 4 months, was classified as low risk and remained stable.
  • No other contributing germline or somatic variants were found, besides polyploidy in chromosomes 7, 12, and 17.

Conclusions:

  • Germline loss-of-function variants in CREBBP may contribute to tumor predisposition in RTS.
  • The findings support the role of CREBBP and EP300 variants in neuroblastoma development.
  • Paired tumor-normal genome sequencing is valuable for analyzing germline tumor predisposition and tumor genomic profiles.